Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

vTv Therapeutics (VTVT) EBT (2016 - 2025)

vTv Therapeutics (VTVT) has disclosed EBT for 12 consecutive years, with -$7.1 million as the latest value for Q4 2025.

  • Quarterly EBT fell 60.87% to -$7.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$31.1 million through Dec 2025, down 37.49% year-over-year, with the annual reading at -$31.1 million for FY2025, 37.49% down from the prior year.
  • EBT hit -$7.1 million in Q4 2025 for vTv Therapeutics, up from -$10.3 million in the prior quarter.
  • In the past five years, EBT ranged from a high of -$841000.0 in Q2 2021 to a low of -$10.3 million in Q3 2025.
  • Historically, EBT has averaged -$6.1 million across 5 years, with a median of -$6.0 million in 2021.
  • Biggest YoY gain for EBT was 83.15% in 2021; the steepest drop was 690.11% in 2021.
  • Year by year, EBT stood at -$9.5 million in 2021, then skyrocketed by 35.78% to -$6.1 million in 2022, then grew by 27.08% to -$4.4 million in 2023, then increased by 0.09% to -$4.4 million in 2024, then crashed by 60.87% to -$7.1 million in 2025.
  • Business Quant data shows EBT for VTVT at -$7.1 million in Q4 2025, -$10.3 million in Q3 2025, and -$7.4 million in Q2 2025.